renibus therapeutics

PREVENT. PROTECT. IMPROVE.

Dedicated to Transforming Outcomes in Cardiothoracic Surgery



RBT-1 Development Program

- Renibus is developing RBT-1, a first-in-class pharmacologic preconditioning agent, to reduce the risk of post-operative complications and improve patient outcomes following cardiothoracic surgery.
- RBT-1 (stannic protoporfin/iron sucrose), upregulates anti-inflammatory, antioxidant and iron-scavenging pathways prior to surgery.
- RBT-1 was granted Fast Track and Breakthrough Therapy Designations by FDA and is currently in Ph3 development.

RBT-1* Quick Facts:

Combination of stannic protoporfin (SnPP) and iron sucrose (FeS)

IV infusion, given 24-48 hrs prior to on-pump CABG and/ or valve surgery

Upregulates cytoprotective anti-inflammatory, antioxidant, and iron-scavenging pathways

*RBT-1 is an investigational product not approved by the FDA

CABG and valve surgery are among the most expensive surgical procedures in the US, with annual costs of $7.3 billion and $5.6 billion, respectively.

Approximately 67% of patients undergoing CABG, valve, or combined CABG/valve surgery experience post-operative complications.

Post-operative complications can have a dramatic impact on patient outcomes, including mortality, morbidity, and quality of life, as well as result in increased costs and utilization of healthcare resources.

CT Surgery: Pathophysiology of Post-operative Complications



Adapted from Fujii Y. Biology 2020, 9, 81.

The development of post-operative complications has been linked to the systemic inflammation and oxidative stress that are associated with cardiovascular disease and exacerbated by surgery.

Post-operative complications include renal failure, atrial fibrillation, vasoplegia, stroke, delirium, need for blood transfusion, prolonged ventilation, prolonged ICU length of stay, among others.

RBT-1 Phase 3 Clinical Study (REN-007 - The PROTECT Study)

protect

ClinicalTrials.gov Listing

- RBT-1* is an investigational drug that upregulates anti-inflammatory, antioxidant, and iron- scavenging pathways, activating a cytoprotective preconditioning response prior to a known insult, such as cardiac surgery.
- The RBT-1-mediated pharmacologic preconditioning is thought to induce broad organ protection, thereby mitigating the risks of post-operative complications, and improving both short- and long-term outcomes.
- The actively enrolling Phase 3 PROTECT trial (REN-007) is designed to confirm the effect of RBT-1 on clinical and patient-centered outcomes (e.g., death, AKI requiring dialysis,intensive care unit (ICU) days, and 30-day cardiopulmonary readmission).

*RBT-1 is an investigational product not approved by the FDA

renibus therapeutics

To learn more about Renibus visit renibus.com or scan the QR code to the right.